$MBRX
Moleculin Biotech, Inc.

2021 Q1 Form 10-Q Financial Statement

#000143774921011755 Filed on May 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.940M $1.810M
YoY Change 7.18% 13.84%
% of Gross Profit
Research & Development $4.105M $3.206M
YoY Change 28.04% 9.35%
% of Gross Profit
Depreciation & Amortization $44.00K $46.00K
YoY Change -4.35% -4.17%
% of Gross Profit
Operating Expenses $6.088M $5.062M
YoY Change 20.27% 10.74%
Operating Profit -$6.088M -$5.062M
YoY Change 20.27% 10.74%
Interest Expense $1.630M $3.850M
YoY Change -57.66% 626.42%
% of Operating Profit
Other Income/Expense, Net $9.000K $5.000K
YoY Change 80.0%
Pretax Income -$4.450M -$1.210M
YoY Change 267.77% -70.05%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.445M -$1.209M
YoY Change 267.66% -70.08%
Net Earnings / Revenue
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$204.0K -$145.4K
COMMON SHARES
Basic Shares Outstanding 28.44M 53.23M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $86.29M $11.65M
YoY Change 640.69% 32.69%
Cash & Equivalents $86.30M $11.65M
Short-Term Investments
Other Short-Term Assets $1.730M $615.0K
YoY Change 181.3% -25.9%
Inventory
Prepaid Expenses
Receivables $1.000K
Other Receivables
Total Short-Term Assets $88.02M $13.79M
YoY Change 538.42% 43.42%
LONG-TERM ASSETS
Property, Plant & Equipment $438.0K $271.0K
YoY Change 61.62% -37.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.77M $11.69M
YoY Change 0.68% 0.0%
TOTAL ASSETS
Total Short-Term Assets $88.02M $13.79M
Total Long-Term Assets $11.77M $11.69M
Total Assets $99.78M $25.47M
YoY Change 291.74% 19.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.928M $1.206M
YoY Change 59.87% -56.91%
Accrued Expenses $2.650M $2.029M
YoY Change 30.61% 62.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.578M $3.235M
YoY Change 41.51% -49.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.690M $6.950M
YoY Change -3.74% 3761.11%
Total Long-Term Liabilities $6.690M $6.950M
YoY Change -3.74% 3761.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.578M $3.235M
Total Long-Term Liabilities $6.690M $6.950M
Total Liabilities $11.27M $10.18M
YoY Change 10.69% 53.87%
SHAREHOLDERS EQUITY
Retained Earnings -$61.40M -$40.80M
YoY Change 50.49% 34.21%
Common Stock $149.8M $56.06M
YoY Change 167.22% 24.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $88.52M $15.29M
YoY Change
Total Liabilities & Shareholders Equity $99.78M $25.47M
YoY Change 291.74% 19.6%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$4.445M -$1.209M
YoY Change 267.66% -70.08%
Depreciation, Depletion And Amortization $44.00K $46.00K
YoY Change -4.35% -4.17%
Cash From Operating Activities -$3.600M -$4.300M
YoY Change -16.28% 11.78%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.000K
YoY Change -100.0% -86.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$2.000K
YoY Change -100.0% -86.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $74.69M $5.291M
YoY Change 1311.55% -4.08%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $74.75M $5.291M
YoY Change 1312.74% -4.17%
NET CHANGE
Cash From Operating Activities -$3.600M -$4.300M
Cash From Investing Activities $0.00 -$2.000K
Cash From Financing Activities $74.75M $5.291M
Net Change In Cash $71.12M $914.0K
YoY Change 7681.18% -44.54%
FREE CASH FLOW
Cash From Operating Activities -$3.600M -$4.300M
Capital Expenditures $0.00 $2.000K
Free Cash Flow -$3.600M -$4.302M
YoY Change -16.32% 11.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28444425
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28444425
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28444425
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11536720
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11536720
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6159000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
709000 USD
CY2021Q1 mbrx Number Of Core Drug Technologies
NumberOfCoreDrugTechnologies
3 pure
CY2021Q1 mbrx Number Of Drug Candidates
NumberOfDrugCandidates
6 pure
CY2021Q1 mbrx Number Of Drugs In Clinical Trials
NumberOfDrugsInClinicalTrials
5 pure
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2020Q1 us-gaap Sublease Income
SubleaseIncome
10000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86293000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15173000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1726000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2025000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
88019000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
17198000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
438000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
483000 USD
CY2021Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2020Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
179000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
202000 USD
CY2021Q1 us-gaap Assets
Assets
99784000 USD
CY2020Q4 us-gaap Assets
Assets
29031000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1928000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1129000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2650000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1791000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4578000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2920000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
127000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
159000 USD
CY2021Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
6563000 USD
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
8192000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
11268000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
11271000 USD
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
28000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
69000 USD
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
149788000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
74671000 USD
CY2021Q1 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
-0 USD
CY2020Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
129000 USD
CY2021Q1 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
61000 USD
CY2020Q4 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
65000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61361000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56916000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
88516000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17760000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99784000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29031000 USD
CY2021Q1 us-gaap Revenues
Revenues
0 USD
CY2020Q1 us-gaap Revenues
Revenues
0 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4105000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3206000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1939000 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1810000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
44000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
46000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
6088000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
5062000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6088000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5062000 USD
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1577000 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3845000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000 USD
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
57000 USD
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4445000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1209000 USD
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21808565
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8321833
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4445000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1209000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-33000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4449000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1242000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4445000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1209000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
44000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
46000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
405000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
397000 USD
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1577000 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3845000 USD
CY2021Q1 mbrx Operating Lease Noncash Expense Net
OperatingLeaseNoncashExpenseNet
113000 USD
CY2020Q1 mbrx Operating Lease Noncash Expense Net
OperatingLeaseNoncashExpenseNet
99000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-299000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-611000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
799000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-947000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
738000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
506000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3624000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4342000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000 USD
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
63000 USD
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
74685000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5291000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74748000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5291000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-4000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-33000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
71120000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
914000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15173000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10735000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86293000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11649000 USD
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
23000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17760000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74684000 USD
CY2021Q1 mbrx Stockholders Equity Adjustments Reverse Stock Split
StockholdersEquityAdjustmentsReverseStockSplit
0 USD
CY2021Q1 mbrx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
116000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
405000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4445000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
88516000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15571000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
566000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
397000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1209000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-33000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
15292000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1200000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3600000 USD
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><b>Use of Estimates -</b> The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors <em style="font: inherit;"> may </em>affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often <em style="font: inherit;"> may </em>yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process <em style="font: inherit;"> may </em>result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </p>
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4400000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4300000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61400000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86300000 USD
CY2021Q1 mbrx Accrued Legal Regulatory Professional And Other Current
AccruedLegalRegulatoryProfessionalAndOtherCurrent
324000 USD
CY2020Q4 mbrx Accrued Legal Regulatory Professional And Other Current
AccruedLegalRegulatoryProfessionalAndOtherCurrent
262000 USD
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
95000 USD
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
78000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2650000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1791000 USD
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
8192000 USD
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
52000 USD
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1577000 USD
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
6563000 USD
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3800000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3100000
CY2021Q1 mbrx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1299000 USD
CY2020Q4 mbrx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
907000 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
810000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
426000 USD
CY2021Q1 mbrx Stock Issued During Period Shares Warrant Exercises
StockIssuedDuringPeriodSharesWarrantExercises
10000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
63000 USD
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
34000 USD
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
33000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
249000 USD
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096 pure
CY2021Q1 mbrx License Agreements Expense
LicenseAgreementsExpense
38000 USD
CY2020Q1 mbrx License Agreements Expense
LicenseAgreementsExpense
61000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
405000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
397000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2021Q1 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
29000 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
29000 USD
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
7000 USD
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
7000 USD
CY2021Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 USD
CY2020Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000 USD
CY2021Q1 us-gaap Lease Cost
LeaseCost
36000 USD
CY2020Q1 us-gaap Lease Cost
LeaseCost
40000 USD
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
10000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
104000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
105000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
56000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10000 USD
CY2021Q1 mbrx Lessee Operating Lease Liability To Be Paid Year Four And Thereafter
LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter
0 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
275000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
26000 USD

Files In Submission

Name View Source Status
0001437749-21-011755-index-headers.html Edgar Link pending
0001437749-21-011755-index.html Edgar Link pending
0001437749-21-011755.txt Edgar Link pending
0001437749-21-011755-xbrl.zip Edgar Link pending
ex_239542.htm Edgar Link pending
ex_239543.htm Edgar Link pending
ex_239544.htm Edgar Link pending
ex_239545.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbrx-20210331.xsd Edgar Link pending
mbrx-20210331_cal.xml Edgar Link unprocessable
mbrx-20210331_def.xml Edgar Link unprocessable
mbrx-20210331_lab.xml Edgar Link unprocessable
mbrx-20210331_pre.xml Edgar Link unprocessable
mbrx20210331_10q.htm Edgar Link pending
mbrx20210331_10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
moleculinlogoresizedclear.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending